Search Results
Attention and Emotional Development in Children
Children with attention problems often feel anxious or worried, and likewise, children who are anxious or worried often have problems with attention. We are looking for children aged 8-12 who may or may not have problems with attention or anxiety to help us understand what happens in the brain that could explain why. You will receive up to $100 gift card for your participation, and informal clinical feedback on your child.
Two in person visits of 2 hours each to the University Park campus, scheduled at the participant(s) convenience
$100
History of seizures or photosensitive epilepsy
PSCI# 18-049 A PHASE II, DOUBLE-BLINDED, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SALVAGE RADIOTHERAPY WITH OR WITHOUT ENHANCED ANTI-ANDROGEN THERAPY WITH APALUTAMIDE IN RECURRENT PROSTATE CANCER
To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone.
To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone.
Post-prostatectomy patients with a detectable serum PSA (≥0.1, but ≤1.0 ng/mL) at study entry (within 90 days of Step 1 registration) a
pN0 or pNx
History/physical examination within 90 days prior to Step 1 registration
Karnofsky performance status of 70-100 within 90 days prior to Step 1 registration
Prior invasive malignancy (except non-melanomatous skin cancer, carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma) unless disease free for a minimum of 2 years
Prior systemic chemotherapy for the study cancer
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
Prior whole gland ablative therapy
Study Driver Characteristics in Mixed Traffic with a Driving Simulator
This is a driving simulator behavioral study. This study aims to investigate drivers' subjective feelings and driving performance in mixed traffic shared by automated vehicles and human-driven vehicles.
This study aims to investigate the effects of drivers’ driving style and automated vehicle penetration rate on drivers’ subjective feelings and driving performance in mixed traffic shared by automated vehicles and human-driven vehicles. There will be one in-person visit for the experiment. This experiment involves driving on a driving simulator and filling out several questionnaires.
$15/hour
Have a valid US driver license for at least one year
Have normal vision or corrected vision only wearing contact lenses
Second Language Learners’ Language Development in Different Modes: Focusing on Complexity, Accuracy, and Fluency
The current study aims to investigate the development of English as a Second Language (ESL) learners' language skills over time, focusing on the interplay between the mode of production (i.e., speech versus written mode) and linguistic features related to complexity, accuracy, and fluency. To address this question, the study will collect spoken and written data from ESL learners in the U.S. at five measurement points throughout an academic year (FA23 to SP24), analyzing their production data using various complexity, accuracy, and fluency measures. The objective is to contribute to the existing body of second language (L2) development research by examining whether the interaction among time, production mode, and proficiency, as well as the varying relationships among the measures, significantly influence the observed outcomes.
Over the course of an academic year (FA23 to SP24), participants will attend five in-person visits, spaced at 7-week intervals. During each visit, they will be asked to write an essay for 20 minutes and deliver a 5-minute spoken monologue in response to prompts similar to those found in the TOEFL speaking section.
$75 ($15 per visit)
non-native English speakers
first-year undergraduate students or students in Intensive English Communication Program
native English speakers
not living in the US
PSCI# 24-014 OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
this trial is examining what happens if a less toxic therapy is given to triple negative breast cancer subjects who's tumor is completely gone after receiving pre surgery chemotherapy.
Participants will need to come to all research visits, reports any side effects of medication, if they are taking any over the counter medications.
ECOG Performance Status 0-2
Triple Negative Breast Cancer
Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy must have been completed preoperatively.
An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization.
No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed.
No evidence of recurrent disease following preoperative therapy and surgery.
No known active liver disease, e.g. due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis
Advanced fMRI Study on the Functional Abnormality of BNST in Anorexia Nervosa Restricting-type
This research is being done to better understand how certain parts of the brain may react differently in people who have a particular eating disorder, anorexia nervosa, which may help us understand why they respond to food in the way they do. This may help us design more effective treatments for people with anorexia nervosa.
You will complete a package of surveys for personality, psychopathology, an evaluation of taste functions, and an MRI/fMRI examination.
Up to a total of $150.
Anorexia nervosa restricting type patients
Healthy volunteer with normal body weight
Fluent in written and spoken English
Pregnancy or breastfeeding
Allergy to milk and milk products
Cannot have MRI due to claustrophobia or specific implants
SHIELD
This trial will address the safety of withdrawing hydroxychloroquine (HCQ) in patients with systemic lupus erythematous who are 60 years of age or older. In this older population the benefits of HCQ are expected to decrease since disease activity decreases with advancing age. The study will test whether HCQ can be safely discontinued in stable/quiescent patients.
Participants will be in this study for about 1 year, during which time they will come to 7 visits in the research clinic. The first visit will take up to 2 hours and will include blood and urine sampling and completion of self-assessment questionnaires. Subsequent visits will take up to 1 hour. Participants will be randomized to receive either the active drug hydroxychloroquine or placebo. The treatment will be blinded to both the participant and the investigator. Diaries will be requested in which the participant keeps track of dosing of the study medication.
Be treated with hydroxychloroquine for at least 7 years
60 years of age or older
stable disease without recent flares
taking more than 5 mg/day prednisone
any signs of active lupus disease.
Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer (PSCI# 21-217) (NRG-GU010)
The purpose of this study is to use the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness. The study will test your tumor tissue for many different genes that all together indicate the risk of your cancer spreading; this is called the Decipher risk score. If you have a higher Decipher risk score, you will be assigned to the part of the study that compares the use of 6 months of hormone therapy and radiation treatment (usual treatment) to the use of darolutamide (BAY 1841788) plus the usual treatment. The purpose of this study is to determine whether the additional drug can reduce the chance that your cancer will come back and spread.
The purpose of this study is to use the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness. The study will test your tumor tissue for many different genes that all together indicate the risk of your cancer spreading; this is called the Decipher risk score. If you have a higher Decipher risk score, you will be assigned to the part of the study that compares the use of 6 months of hormone therapy and radiation treatment (usual treatment) to the use of darolutamide (BAY 1841788) plus the usual treatment. The purpose of this study is to determine whether the additional drug can reduce the chance that your cancer will come back and spread.
ECOG Performance Status of 0-2 within 120 days prior to registration;
For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months
Previous bilateral orchiectomy
Prior radiotherapy to the prostate/pelvis region that would result in overlap of radiation therapy fields.
Active testosterone replacement therapy; any replacement therapy must be stopped at least 30 days prior to registration
Inability to swallow oral pills.
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER (PSCI# 20-133) (GO42784)
The purpose of this study is to compare the effects, good or bad, of giredestrant versus an approved endocrine therapy (a treatment that blocks or removes hormones), on patients with breast cancer. In this study, subjects will get either giredestrant or a drug chosen specifically by the study doctor. Subjects can participate in this study based on breast cancer characteristics, current condition, and how well previous anti-cancer therapies were tolerated.
• You should not join another research study. • For women: If you can become pregnant, you must use a reliable non-hormonal birth control method during the study and for 9 days after your final dose of giredestrant or, if you are in the group receiving approved endocrine therapy prescribed by the study doctor, a period of time that your study doctor will discuss with you. This will be 21 days after if you are prescribed letrozole or anastrozole, 30 days after if you are prescribed exemestane, and 60 days after if you are prescribed tamoxifen. Talk with your study doctor about what birth control method may be best for you. Depending on the study treatment you receive, you might be restricted from donating eggs during this same period. Tell your study doctor right away if you get pregnant during this period. If you get pregnant, the study doctor will want to follow up with you on the outcome of the pregnancy and collect information on the baby. • For men: you must agree to take precautions as outlined below for each treatment arm: –If you are in the group receiving approved endocrine therapy prescribed by the study doctor, you study doctor will discuss with you what precautions you will need to take. –If you are in the group receiving giredestrant, and your partner is pregnant or able to become pregnant, you must use a condom during the study and for 9 days after your final dose of giredestrant. This will be 21 days after if you are prescribed letrozole or anastrozole, 30 days after if you are prescribed exemestane, and 90 days after if you are prescribed tamoxifen. You must not donate sperm during this same period. Tell your study doctor right away if your partner becomes pregnant during these periods. The study doctor or research staff will advise you of the possible risks to your unborn child and will make an effort to contact your partner to get her permission to collect information about the pregnancy and the baby. No matter what your partner decides, you can continue to take part in this study. • You should not use certain medications during this study. Your study doctor will talk to you about these medications.
Participants who have documented ER+ tumor by immunohistochemistry, as assessed locally on a primary disease specimen and defined as 1% of tumor cells stained positive according to the ASCO/College of American Pathologists (CAP) guidelines
Participants who have documented HER2- tumor, as assessed locally on a primary disease specimen and defined according to ASCO/CAP guidelines
Participants must have undergone definitive surgery of the primary breast tumor(s)
Participants who received or will be receiving adjuvant chemotherapy must have completed adjuvant chemotherapy prior to randomization
Participants who have received treatment with investigational therapy within 28 days prior to initiation of study treatment or is currently enrolled in any other type of medical research
Participants receiving or planning to receive a CDK4/6i as adjuvant therapy
Participants who have active cardiac disease or history of cardiac dysfunction
Participants who have been diagnosed with Stage IV breast cancer
Multimodal brain MRI-guided understanding of non-motor outcomes in Parkinson's post DBS
This study will explore the relationship between multimodal brain MRI findings and cognitive/mood outcomes in Parkinson's Disease (PD) patients following Deep Brain Stimulation (DBS). Patients already planning to undergo DBS for PD who choose to take part in this study will have study visits before and after DBS to collect motor, neurobehavioral and physical therapy measurements.
Patients who are already planning to undergo DBS for PD who choose to take part in this study will have study visits before and after DBS surgery to collect motor, neurobehavioral and physical therapy measurements. While many of these components are part of as standard of care, some assessments will need to be collected specifically for research purposes. There are two in-person visits (one before DBS surgery and one approximately 3-6 months after surgery). As part of the study, an MRI to gather data to answer our research questions will be conducted. This is in addition to the clinical MRI that is part of the regular assessment to determine if an individual is suitable for the DBS surgery.
$130 if components of study are completed
Diagnosed with Parkinson's Disease
Undergoing DBS as part of standard of care
Able to provide informed consent
General contraindications to surgery
Pregnant or nursing women
Unable to undergo MRI for any reason
Atypical Parkinsonism
PSCI 23-121 Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
This study is looking at patients with oligometastasis comparing chemotherapy and SABR with chemotherapy alone
• Blood counts and blood chemistry done at initiation and every three months to make sure you are not having any side effects from the study affecting your blood counts. • CT or MRI scans done at initiation and every three months to monitor the response of the treatment to your cancer • Physical exams done every three months to confirm your general well-being and to detect side effects from the study. Compete physical and well being form as set below: • Baseline • 3 months from start of treatment • 6 months from start of treatment • 9 months from start of treatment • 12 months from start of treatment • 18 months from start of treatment • 24 months from start of treatment
patient may not have brain metastases
Patient may have any RCC histology except a histology that has a sarcomatoid component.
Patient must have a pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma (RCC) prior to randomization.
Patient must have primary site addressed by local therapy. If the primary RCC is intact, the patient must undergo local treatment to the primary before randomization.
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used
Patients must not expect to conceive until after 6 months after the last dose of protocol medication
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
In order to participate in the QOL portion of the protocol, the patient must speak English or Spanish.
The association between perceived parenting styles, intolerance of uncertainty, and anxiety among young adults
This study aims to understand the association between young adults' perceived parenting, intolerance of uncertainty, and trait anxiety. Participant will be asked to complete a questionnaire that aims to answer the environment and parenting beliefs around which they were brought up, and if they face stressors and anxieties associated with them. This is a correlational study
Geographical location: USA
All genders
All ethnicities
Individuals over 34 years
Individuals residing outside USA
The effects of local negative pressure on forearm and skin blood flow in humans
This study continues our exploration into the mechanisms underlying the control of blood flow. During the experiments, we noninvasively measure skin blood flow (SkBF) and forearm blood flow (FBF) with a FLPI and venous occlusion plethysmography (VOP), respectively. The FLPI uses a low energy laser to measure SkBF. VOP uses blood pressure cuffs on the upper arm and wrist, and an elastic strain gauge encircling the forearm between the cuffs to measure the change in forearm-circumference over time from which we calculate FBF. For each experiment, we collect SkBF and FBF data for a 20-minute baseline, expose the skin of the forearms to negative pressure and then collect SkBF and FBF data for an additional 30-90 minutes. Each subject participates in 2 experiments that differ only in the protocol for the application of negative pressure (i.e. continuous, pulse).
• Individuals that use nicotine-containing products
Illicit or recreational drug-use
• Taking corticosteroids, anticoagulants, NSAIDS, or blood thinners
Pregnancy
TMIST_EA1151
This study is being done to answer the following question: Can tomosynthesis mammography, three-dimensional x-ray imaging of the breast, lower your chance of developing life-threatening breast cancer through routine screening compared with digital mammography, two-dimensional x-ray imaging of the breast? We are doing this study because we want to find out which of the two usual approaches to breast cancer screening are better in the early detection of life-threatening breast cancers.
If you decide to take part in this study, you will either get screened for breast cancer with digital mammography every year or two for up to 5 years, or tomosynthesis mammography every year or two for up to 5 years. After you finish the active study screening period, you will return to your normal screening mammography regimen and the study team will check with you and/or your medical records for your health status once a year for at least three years and up to 8 years after enrollment in the study. The date of your enrollment in the study determines the number of years of your participation.
Patients must be scheduled for, or have intent to schedule, a screening mammogram.
Patients must be able to tolerate digital breast tomosynthesis and fullfield digital mammographic imaging required by protocol.
Patients must be willing and able to provide a written informed consent.
Patients must not have new symptoms or signs of benign or malignant breast disease
Patients must not have had a screening mammogram within the last 11 months prior to date of randomization.
Patients must not have previous personal history of breast cancer including ductal carcinoma in situ
Patients must not currently have breast enhancements (e.g., implants or injections).
A Phase II/III Study of Maintenance Nivolumab versus Observation in HPV Positive OPCA (PSCI# 20-016) (EA3161)
The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment. The addition of nivolumab to the usual treatment could shrink your cancer or prevent it from returning. But, it could also cause side effects, which are described in the risks section below. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the nivolumab increases the lifetime of the patient without progression for 10 years. This immunotherapy drug, nivolumab, is already approved by the FDA for use in advanced and incurable head and neck cancer. But, most of the time it is not used until the cancer is very advanced and chemotherapy stops working. In this study we believe the use of nivolumab has a chance of preventing the cancer from coming back for patients with your type of cancer. There will be about 286 people taking part in the first part (phase II) of the study and 458 more people taking part in second part (phase III), if the results of the phase II portion are promising and if there is evidence that nivolumab may prolong your life.
The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment.
ECOG performance status of 0 or 1.
Patients must have oropharynx cancer that is p16-positive by immunohistochemistry
Adequate baseline organ and marrow function
Adequate baseline liver functionality
Patients must not have had prior systemic therapy or radiation treatment for p16 positive OPSCC
Patients must not have received previous irradiation for head and neck, tumor, skull base, or brain tumors
Patients must not have known hypersensitivity to nivolumab
Patients with evidence of distant metastases or leptomeningeal disease are excluded
Factors Influencing the Decision to Report Sexual Violence on Campus
Research project to understand why students do or do not choose to report sexual assault exposure to police or university officials.
One interview via video conferencing or in person. Optional follow up interview via video conferencing.
$35 for initial interviews; $12 for follow ups
experienced unwanted sex, assault, or harassment during higher education study
currently in undergraduate or graduate program
recently graduated, transferred, or pausing higher education program
Racial background is Black, Afro-Latina, Afro-Indigenous, Black Multiracial
Angiotensin-(1-7) Cardiovascular Effects in Aging
We will investigate the effects of acute intravenous infusion of the hormone, angiotensin-(1-7), on cardiovascular function in healthy older adults in a randomized, double blind, placebo-controlled, crossover study.
Participation in this study will include three separate visits to the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. Participants will first have a screening visit to determine if they are able to participate in this study. If eligible based on the screening visit, they will participate in two study visits separated by at least one week. At each study visit, they will be infused with doses of a placebo or angiotensin-(1-7) for about two hours. Before and at the end of the infusion, we will measure blood pressure and blood flow, nerve activity with an acupuncture-type needle in your leg, and collect blood samples from a small plastic tube (catheter) placed in the arm. Cells will also be collected from inside the vein using the catheter if the participant is willing. The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples and endothelial cells (if willing) will be collected at baseline and at the end of infusions. Blood pressure, heart rate, and muscle sympathetic nerve activity via microneurography will be measured throughout the study.
$25 per hour; additional $25 per study visit for cell collection
Body Mass Index between 18.5-30 kg/m2
Blood pressure less than 130/80 without medication
No serious chronic medical problems
Fluent in written and spoken English
History of cardiovascular, liver, or kidney disease
Taking certain medications (such as SNRIs, NET inhibitors, anticoagulants, glucocorticoids)
Women who are pregnant, nursing, or taking hormone replacement therapy
Evidence of diabetes
Investigation of Digital Media Use, Anxiety, and Biobehavioral Emotion Regulation in Adolescents
Over the past few decades, the social world of teens has been transformed by the use of digital technology. This study will examine associations between digital media use and emotions in adolescents' daily lives. Youth and their parent will complete questionnaires and semi-structured clinical interviews regarding the youth’s emotions, social experiences, and possible anxiety symptoms. For 10 consecutive days, youth will complete one computerized task once per day and four mini questionnaires via the Wear-It app on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours. Six months later, all youth will be asked to repeat one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. One year after enrollment, participants will complete final questionnaires, interviews, one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours.
Over the past few decades, the social world of teens has been transformed by the use of digital technology. This study will examine associations between digital media use and emotions in adolescents' daily lives. Youth and their parent will complete questionnaires and semi-structured clinical interviews regarding the youth’s emotions, social experiences, and possible anxiety symptoms. For 10 consecutive days, youth will complete one computerized task once per day and four mini questionnaires via the Wear-It app on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours. Six months later, all youth will be asked to repeat one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. One year after enrollment, participants will complete final questionnaires, interviews, one computerized task once per day and four mini questionnaires via the Wear-It App on the youth's mobile device. Some youth will also participate in a lab visit that will last approximately two hours.
$495
Speak, write and read English
Must reside and participate from the US
Neurological disorders (ie, Autism, seizures)
Youth of parent not between 14-16.9 years of age
Those not residing in or participating from the US
Strengths, Outcomes, Adversity, and Resilience in College-Aged Childhood Cancer Survivors: The PSU SOAR Study
The purpose of this study is to analyze the strengths, outcomes, adversity, and resilience, as indicated by self-reported experiences in college students who may or may not be childhood cancer survivors. We are asking college students aged 18-23 years attending 4 year universities in the United States to report on their childhood health experiences and their current mental, physical, and social well being during college using a confidential survey. We plan to recruit students who have or have not had a childhood history of cancer and will also ask questions about their demographic information and health habits.
The participants will be asked to complete a confidential online survey that will take 10-15 minutes to complete.
Participants are eligible to earn a $75 Amazon gift card through a random drawing that they can choose to enter after submitting their survey responses
College student attending 4 year university
English as primary language
Not attending a 4 year university
Does not have English as primary language
PSCI #24-126 A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer.
This study is for subjects who have removable pancreatic cancer. If subjects decide to take part in this study, subjects will either get the study drugs FOLFIRINOX for about 4 months followed by surgery and then more FOLFIRINOX for about 2 months, or subjects will get surgery followed by FOLFIRINOX for about 6 months. After subjects finish their treatment, the subject's doctor will continue to watch them for side effects. They will check subjects in the clinic every 4 months for 2 years after you started the study. After that, they will check subjects either in the clinic or by phone every 6 months for 6 years after the subject started the study. This means that the subject will keep seeing or hearing from their doctor for 6 years after they started the study.
Subject will either get the study drugs FOLFIRINOX for about 4 months followed by surgery and then more FOLFIRINOX for about 2 months, or the subjects will get surgery followed by FOLFIRINOX for about 6 months. After treatment the doctor will continue to watch for side effects. They will check on the subjects in the clinic every 4 months for 2 years after the subject started the study. After that, they will check the subject either in the clinic or by phone every 6 months for 6 years after you started the study. This means that the subject will keep seeing or hearing from your doctor for 6 years after you started the study.
No evidence of metastatic disease
Less than 180° interface between tumor and vessel wall of the portal vein or superior mesenteric vein, and patent portal vein/splenic vein confluence
No involvement or abutment of the celiac artery, common hepatic artery, superior mesenteric artery, or replaced right hepatic artery (if applicable)
Age ≥ 18 years
comorbid conditions that would prohibit curative-intent pancreatectomy
ECOG Performance Status greater than 0-1
Interlimb differences in Motor Control and Learning
This study examines how each brain hemisphere contributes to motor control and coordination. Participants play virtual reality/computer games to look at how their arms move during different activities.
Participants play 2D virtual reality/computer games by making reaching movements with position tracking sensors attached to their hands and upper arms.
15
upper-extremity orthopedic injuries that interfere with participation
PSCI 23-144 NRG-LU008: PHASE III PROSPECTIVE RANDOMIZED TRIAL OF PRIMARY LUNG TUMOR STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY CONCURRENT MEDIASTINAL CHEMORADIATION FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
Patients diagnosed withy inoperable node positive non small cell lung cancer will be randomized to with radiation therapy to all know sites of disease in the lung, followed by immunotherapy or radiation to the primary lung tumor, followed by radiation to the lymph nodes followed by immunotherapy
Participants will be required to come to all study visits, report to the study doctor any new medications, prescription or over the counter that they may be taking,
The patient must be deemed clinically appropriate for curative intent definitive combined modality therapy, based on the following staging assessments:
No evidence of distant metastases based on FDG PET/CT scan obtainedwithin 60 days of registration.
Primary tumor ≤ 7 cm;
Age ≥ 18;
Patients without identifiable primary tumor
Centrally located primary tumor < 2 cm from involved nodal disease which would result in significant overlap of the primary SBRT and nodal radiation fields
Participants who are pregnant or unwilling to discontinue nursing.
Participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) unwilling to use highly effective contraceptives during therapy
Normalizing preteen HPV vaccination with practice-based communication strategies (Protect Them)
This study seeks to adapt and test a culturally-relevant, web-based game intervention to motivate Spanish-speaking preteens to initiate and complete human papillomavirus (HPV) vaccination. The present study will adapt an existing web-based game developed as an educational tool on HPV vaccination for English-speaking preteens in North Carolina. The study includes the recruitment of paired dyads (Spanish-speaking preteens and parents) to focus groups to evaluate the acceptability of cultural adaptations to the existing web-based game intervention. We will recruit up to 25 parents and preteens ages 11-12 who will receive a link to the Spanish game to play for 7-10 days in advance of the focus group discussions. The focus groups will ask participants about cultural and language adaptations to the existing game and how they react to a game that will serve as an interactive, educational tool on HPV vaccination. The focus groups will take place in Harrisburg, PA between January and March of 2018. No health information will be collected as part of this study.
Not vaccinated with the HPV vaccine
Have computer, tablet, or smartphone
How Immigration Looks to America: Perspectives of the Photographic Portrayals of Immigrants in News Photographs
This study will involve surveying college students regarding their perceptions about how immigrants are portrayed in news media.
Dynamic Assessment of Vocabulary Learning Strategies
To provide better understanding of Chinese students' vocabulary learning Strategies and help develop better learning strategies
Complete seven sessions, which may take approximately 20-30 minutes of your time per session. Read several English short texts and identify meanings of target words. Possibly participate in a virtual interview that will be scheduled at your convenience.
Adult English learners
Currently enrolled in a college or university
Not Chinese
CCTG MA.39- A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Purpose of this study is to compare any good and bad effects of not using regional radiotherapy to using radiotherapy. The study will help researcher learn if not giving regional radiotherapy is just as good as using regional therapy to treat node positive breast cancer in women.
Blood will be drawn at two time points and number of visits will be determined by the individual radiation treatment plan.
No evidence of metastasis
1 - 3 positive lymph nodes
May have had breast conserving surgery or mastectomy
35 years of age or older
History of ipsilateral breast cancer or DCIS
Synchronous or contralateral breast cancer
pT4 disease
Neoadjuvant Chemotherapy for breast cancer
Dining Out in NYC: Using VR to investigate the influence of multisensory urban design factors on eating behavior in emerging adults
This study uses virtual reality to investigate how sensory aspects of an environment influence eating behavior. Specifically, subjects will be immersed in a virtual outdoor café environment and consume a standardized meal while being exposed to either a pleasant or unpleasant smell. Total food intake and mood will be measured following each visit.
Answer initial screening and demographics questionnaires. Two in-person visits to the lab to experience a VR setting and consume a provided meal. One visit will include a small hair sample. Answer questionnaires following the VR experience.
$20 in pre-paid gift card
Fluent in English
Not color blind or nose blind
No food allergies/sensitivities
No diagnosis of mental or physical disabilities that may affect appetite, eating behavior, or body awareness and balance (such as eating disorders, Major Depressive Disorder, epilepsy, and vertigo)
Not fluent in English
Color blind or nose blind
Self-reported food allergies/sensitivities
Have diagnosis of mental or physical disabilities that may affect appetite, eating behavior, or body awareness and balance (such as eating disorders, Major Depressive Disorder, epilepsy, and vertigo)
A Confirmatory Phase 3 Mutlicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL).
The purpose of this trial is to evaluate the safety and efficacy of 18 weeks of HyBryte (topical gel) treatment in combination with visible light therapy in subjects with cutaneous T-cell lymphoma when compared to placebo (no active ingredient). Cutaneous T-cell lymphoma (CTCL), of which the most common early stages are also known as mycosis fungoides (MF), is the most common type of T cell lymphoma. Participants will be enrolled in this trial for 30 weeks and will follow up at the clinic site every 4 weeks following the last trial treatment for a total of 12 weeks.
Participants will attend in person visits over 30 weeks. At different timepoints throughout the study participants will have their skin evaluated and photographed, have blood drawn, have an ECG done, and apply the study medication as directed by the study team.
Participants must have a minimum of 3 evaluable, discrete lesions
Participants must be willing to follow the clinical protocol and voluntarily give their written informed consent
Participants with extensive skin disease may not be eligible to participate; investigator will discuss during skin evaluation
Certain medical conditions may not be eligible to participate; study coordinator will discuss further.
EA8183 A Phase III Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE) (PSCI# 21-122)
This study is being done to answer the following question: Will the addition of a new drug, darolutamide, to standard Androgen Deprivation Therapy (ADT) (a hormonal therapy that is a usual approach to treatment) after surgery cure more men with prostate cancer than using Androgen Deprivation Therapy alone? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.
This study is being done to answer the following question: Will the addition of a new drug, darolutamide, to standard Androgen Deprivation Therapy (ADT) (a hormonal therapy that is a usual approach to treatment) after surgery cure more men with prostate cancer than using Androgen Deprivation Therapy alone? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.
Patient must have undergone a radical prostatectomy (RP) and must be preregistered to Step 0 of this study at least 6 weeks after but not more than 12 weeks after their radical prostatectomy.
Patient must not have any previous treatment with androgen deprivation therapy (ADT), chemotherapy, or other physician prescribed systemic therapy for treatment of their prostate cancer.
Patient must have an ECOG performance status of 0-2.
Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure).
Comparing runners’ perception of their biomechanics through validation of RunScribe wearable technology in an outdoor environment.
Comparing runners' perceptions of their running gait biomechanics to actual mechanics using RunScribe wearable technology validated drone video capture and subsequent kinematic analysis in a natural outdoor running environment.
You will complete a survey and be asked to run a short distance on a track at your typical long distance pace while being filmed by a drone and while wearing a wearable RunScribe device on your shoe.
$50
No prior or current running injuries in the past 3 months
Runs at least 15 km per week
Able to speak English
Current musculoskeletal injury
Currently under medical supervision or not cleared for running
Congenital or traumatic deformity resulting in altered bone alignment
No prior outdoor running experience